Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 63Neoplasms 5Neoplasm Metastasis 5Carcinoma, Intraductal, Noninfiltrating 3Breast Neoplasms, Male 3Recurrence 2Ovarian Neoplasms 2Endometrial Neoplasms 2Breast Diseases 2Uterine Cervical Neoplasms 1Unilateral Breast Neoplasms 1Tuberous Sclerosis 1Squamous Cell Carcinoma of Head and Neck 1Sexual Dysfunctions, Psychological 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Neuroendocrine Tumors 1Neoplasms by Site 1Multiple Endocrine Neoplasia Type 1 1Locoregional Recurrence 1Hyperglycemia 1Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer 1Hereditary Sensory and Autonomic Neuropathies 1Head and Neck Neoplasms 1HER2-positive Breast Cancer 1Granulosa cell tumor of the ovary 1Endometrial Stromal Tumors 1Endometrial Hyperplasia 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1

Interventions

trastuzumab biosimilar HLX02 1exemestane 1X-Rays 1Trastuzumab 1Taxes 1TVB-2640 1Specimen Handling 1Paclitaxel 1PF-05280014 1Ontruzant 1Ogivri 1Magnetic Resonance Spectroscopy 1Letrozole 1Fulvestrant 1Disulfides 1CT-P6 1Biopsy 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Breast Carcinoma × exemestane × 1 year × Clear all
NCT03179904 2026-05-05

TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer

Mayo Clinic

Phase 2 Active not recruiting
17 enrolled 10 charts
Breast

Advanced Breast Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡